Biogen’s investigational Alzheimer’s disease treatment aducanumab granted FDA Fast Track Designation

Company also provides update on new interim analysis from Phase Ib study.

“By collaborating with regulators through programs like Fast Track, we hope to bring effective treatments to patients and families affected by Alzheimer’s disease as quickly as possible,” said Alfred Sandrock, executive vice president and chief medical officer at Biogen.

Aducanumab is currently being evaluated in two global Phase III studies, ENGAGE and EMERGE, which are designed to evaluate its safety and efficacy in slowing cognitive impairment and the progression of disability in people with early Alzheimer’s disease.

Update: Phase Ib Data

PRIME is the ongoing Phase Ib randomized, double-blind, placebo-controlled, multiple-dose study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical effects of aducanumab in patients with prodromal or mild AD.

The placebo-controlled portion of the study included fixed doses of aducanumab at 1, 3, 6 and 10 mg/kg and a titration regimen. PRIME also has a long-term extension for patients who completed the one-year placebo-controlled portion of the study.

In a recently completed interim analysis from PRIME, efficacy and safety data were consistent with results previously reported. These data support the design of the ongoing Phase 3 ENGAGE and EMERGE studies. Biogen plans to share detailed information about these results at upcoming medical meetings.